Brenner Robert 4

What Happened

• Robert Brenner, Chief Medical Officer of Vera Therapeutics (VERA), received equity awards on February 4, 2026: 25,000 shares of Class A common stock and 50,000 restricted stock units (RSUs) reported as a derivative grant. Both were reported at a $0.00 price (i.e., compensation awards), for 75,000 shares/RSUs total. These are grants/awards (transaction code A), not open-market purchases or sales.

Key Details

• Transaction date: February 4, 2026. Filing date: February 6, 2026 (filed within the typical 2‑business‑day Form 4 window).
• Price: $0.00 per share (compensation grant); total reported value listed as $0 for the acquisition lines.
• Vesting/derivative details:
  • Footnote F1: The 50,000 RSUs represent shares underlying RSUs that vest one‑fourth on each February 20 in 2027, 2028, 2029 and 2030, subject to continuous service.
  • Footnote F3: Separately noted option vesting schedule — 1/48th vests on March 4, 2026 and monthly thereafter, subject to service.
  • Footnote F2: Filing also references 624 shares acquired under the company ESPP on March 13, 2025.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Reported promptly (Feb 6 filing for Feb 4 transactions); not indicated as late.

Context

• These are compensation awards, common for executives; RSUs are a derivative grant and do not convert to transferable shares until they vest per the schedule above. Awards at $0 reflect grant accounting, not a market purchase. No sale or exercise occurred in this filing.